Recursion Pharmaceuticals (RXRX) Revenue (2020 - 2026)
Recursion Pharmaceuticals (RXRX) revenue from Mar 31, 2020 to Mar 31, 2026. The TTM Recursion Pharmaceuticals (RXRX) revenue is $66M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual Revenue
Quarterly Revenue
Recursion Pharmaceuticals (RXRX) Revenue CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +11.05% |
| 3 Years TTM | +12.50% |
| 5 Years TTM | +59.37% |
| All Time TTM | +59.38% |
Annual Revenue change of Recursion Pharmaceuticals (RXRX)
| Year | Revenue | Change |
|---|---|---|
| 2026 | $6.47M | -91.34% |
| 2025 | $75M | +26.92% |
| 2024 | $59M | +31.99% |
| 2023 | $45M | +11.90% |
| 2022 | $40M | +291.36% |
| 2021 | $10M | +157.07% |
| 2020 | $3.96M | +70.69% |
| 2019 | $2.32M | N/A |
Comparison Recursion Pharmaceuticals (RXRX) five years revenue CAGR with competitors
Recursion Pharmaceuticals (RXRX) five years revenue CAGR is 59.35%.